Partial corrections were made to the Medium- to Long-Term Growth Strategy 2026 as a rolling update. Financial forecasts were revised to present outlooks toward fiscal year 2031, amending the previous targets for fiscal year 2030. Dividend payout ratio expression was changed to an outlook.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4527","jir_company_name":"Rohto Pharmaceutical Co.,Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4527-20261005-01.pdf","jir_short_summary":"Partial corrections were made to the Medium- to Long-Term Growth Strategy 2026 as a rolling update. Financial forecasts were revised to present outlooks toward fiscal year 2031, amending the previous targets for fiscal year 2030. Dividend payout ratio expression was changed to an outlook.","jir_summary":"### Summary of Corrections\nRohto Pharmaceutical Co.,Ltd. announced corrections to parts of the Medium- to Long-Term Growth Strategy 2026, released on October 2, 2026, due to errors. The corrections, prepared on a rolling basis, primarily include revisions to the fiscal year 2031 financial forecast, upward adjustments to the prior fiscal year 2030 forecast, and corrections to the expression of the dividend payout ratio.\n\n### Impact and Outlook\nAs a result of these corrections, a new financial forecast for fiscal year 2031 is presented, with raised targets for net sales and operating income, and a clarified outlook for the dividend payout ratio. The company intends to continue its policy of flexible forecasting and outlook adjustments through rolling updates.","jir_financial_highlights":"Fiscal Year 2031 Financial Forecast: Net sales 4,640 hundred million yen, Operating income 598 hundred million yen, Operating margin 12.9% (Revised from previous forecast. Fiscal year 2030 forecast also revised upward to Net sales 4,440 hundred million yen, Operating income 568 hundred million yen, Operating margin 12.8%)\nDividend Payout Ratio: Expected to be at a DOE of 4.0% (Corrected a previous misstatement and changed to an outlook)","jir_category":"","jir_hashtags":"#RohtoPharmaceutical, #MediumToLongTermGrowthStrategy, #DisclosureUpdate","jir_key_figures":"Fiscal year 2031 Net sales: 4,640 hundred million yen\nFiscal year 2031 Operating income: 598 hundred million yen\nFiscal year 2031 Operating margin: 12.9%","jir_meta_title":"Rohto Pharmaceutical: Notice of Correction to Medium- to Long-Term Growth Strategy | FY2031 Outlook and Dividend Payout Outlook","jir_meta_description":"Rohto Pharmaceutical Co.,Ltd. announced corrections to the Medium- to Long-Term Growth Strategy 2026. Revised financial forecasts for fiscal year 2031, upward revision of FY2030 forecasts, and an updated dividend payout outlook were disclosed. The rolling update policy will continue.","jir_og_title":"Rohto Pharmaceutical Announces Correction to Medium- to Long-Term Growth Strategy","jir_og_description":"Revised financial forecast for fiscal year 2031, upward revision of FY2030 forecasts, and updated dividend payout outlook. The company will continue its rolling update policy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7770,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-127251","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n